Grace Therapeutics (GRCE) Capital Expenditures (2019 - 2024)
Grace Therapeutics (GRCE) posted Capital Expenditures of $22000.0 for Q1 2024, up 175.0% sequentially from $8000.0 in Q1 2023, and up 175.0% YoY from $8000.0 in Q2 2023.
Grace Therapeutics (GRCE) Capital Expenditures (2019 - 2024) Analysis & Trends
Grace Therapeutics has reported Capital Expenditures for 5 years, with the latest figure at $22000.0 in Q1 2024.
- Quarterly Capital Expenditures rose 175.0% year-over-year to $22000.0 in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $22000.0 (up 29.41% YoY) and the FY2024 annual result came in at $22000.0, up 29.41% from the prior year.
- Capital Expenditures advanced to $22000.0 in Q1 2024 per GRCE's latest filing, from $8000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $319000.0 in Q1 2020 and troughed at $2000.0 in Q3 2022.
- A 4-year average of $61000.0 and a median of $22000.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2020 and 2024: Capital Expenditures jumped 89.47% in 2020, then surged 175.0% in 2024.
- Over 4 years, Capital Expenditures stood at $33000.0 in 2020, then plunged by 93.94% to $2000.0 in 2022, then jumped by 300.0% to $8000.0 in 2023, then soared by 175.0% to $22000.0 in 2024.
- According to Business Quant data, Capital Expenditures over the past three periods registered $22000.0, $8000.0, and $2000.0 for Q1 2024, Q1 2023, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 251.02 Mn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 22,000.00 |
| Mar 31, 2024 | 22,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Mar 31, 2023 | 8,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Sep 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 7,000.00 |
| Sep 30, 2020 | 33,000.00 |
| Sep 30, 2020 | 33,000.00 |
| Jun 30, 2020 | 36,000.00 |
| Jun 30, 2020 | 36,000.00 |
| Mar 31, 2020 | 319,000.00 |
| Mar 31, 2020 | 319,000.00 |
| Dec 31, 2019 | 254,000.00 |
| Dec 31, 2019 | 254,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Sep 30, 2019 | 17,000.00 |
| Jun 30, 2019 | 19,000.00 |
| Jun 30, 2019 | 19,000.00 |